HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 30

PMID 33919468

Citations 11

Authors

Andreia Gameiro

Catarina Nascimento

Jorge Correia

Fernando Ferreira

Affiliations

Soon will be listed here.

Abstract

Feline mammary carcinoma (FMC) is a highly prevalent tumor, showing aggressive clinicopathological features, with HER2-positive being the most frequent subtype. While, in human breast cancer, the use of anti-HER2 monoclonal antibodies (mAbs) is common, acting by blocking the extracellular domain (ECD) of the HER2 protein and by inducing cell apoptosis, scarce information is available on use these immunoagents in FMC. Thus, the antiproliferative effects of two mAbs (trastuzumab and pertuzumab), of an antibody-drug conjugate compound (T-DM1) and of combined treatments with a tyrosine kinase inhibitor (lapatinib) were evaluated on three FMC cell lines (CAT-MT, FMCm and FMCp). In parallel, the DNA sequence of the ECD (subdomains II and IV) was analyzed in 40 clinical samples of FMC, in order to identify mutations, which can lead to antibody resistance or be used as prognostic biomarkers. Results obtained revealed a strong antiproliferative effect in all feline cell lines, and a synergistic response was observed when combined therapies were performed. Additionally, the mutations found were not described as inducing resistance to therapy in breast cancer patients. Altogether, our results suggested that anti-HER2 mAbs could become useful in the treatment of FMC, particularly, if combined with lapatinib, since drug-resistance seems to be rare.

Citing Articles

Recent Issues in the Development and Application of Targeted Therapies with Respect to Individual Animal Variability.

Kurhaluk N, Tkaczenko H Animals (Basel). 2025; 15(3).

PMID: 39943214 PMC: 11815764. DOI: 10.3390/ani15030444.

Level of Necrosis in Feline Mammary Tumors: How to Quantify, Why and for What Purpose?.

Rodrigues-Jesus J, Canadas-Sousa A, Santos M, Oliveira P, Figueira A, Marrinhas C Animals (Basel). 2024; 14(22).

PMID: 39595332 PMC: 11591325. DOI: 10.3390/ani14223280.

The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies.

Guo H, Xu X, Zhang J, Du Y, Yang X, He Z Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204153 PMC: 11357454. DOI: 10.3390/ph17081048.

Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).

PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.

Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.

Yu T, Yamamoto H, Morita S, Fukushima R, Elbadawy M, Usui T J Vet Med Sci. 2024; 86(3):317-321.

PMID: 38281758 PMC: 10963087. DOI: 10.1292/jvms.23-0448.

References

Cheung K . Treatment Strategies and Survival Outcomes in Breast Cancer. Cancers (Basel). 2020; 12(3). PMC: 7140050. DOI: 10.3390/cancers12030735. View

Appert-Collin A, Hubert P, Cremel G, Bennasroune A . Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015; 6:283. PMC: 4657385. DOI: 10.3389/fphar.2015.00283. View

Gearing D, Huebner M, Virtue E, Knight K, Hansen P, Lascelles B . In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats. J Vet Intern Med. 2016; 30(4):1129-37. PMC: 5094543. DOI: 10.1111/jvim.13985. View

Gaibar M, Beltran L, Romero-Lorca A, Fernandez-Santander A, Novillo A . Somatic Mutations in and Implications for Current Treatment Paradigms in -Positive Breast Cancer. J Oncol. 2020; 2020:6375956. PMC: 7081042. DOI: 10.1155/2020/6375956. View

Yao H, He G, Yan S, Chen C, Song L, Rosol T . Triple-negative breast cancer: is there a treatment on the horizon?. Oncotarget. 2016; 8(1):1913-1924. PMC: 5352107. DOI: 10.18632/oncotarget.12284. View

Maniscalco L, Iussich S, Martin de Las Mulas J, Millan Y, Biolatti B, Sasaki N . Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J. 2011; 191(1):65-71. DOI: 10.1016/j.tvjl.2010.12.016. View

Burguin A, Furrer D, Ouellette G, Jacob S, Diorio C, Durocher F . Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines. PLoS One. 2020; 15(6):e0234991. PMC: 7316326. DOI: 10.1371/journal.pone.0234991. View

Richard S, Selle F, Lotz J, Khalil A, Gligorov J, Soares D . Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc. 2016; 88 Suppl 1:565-77. DOI: 10.1590/0001-3765201620150178. View

Metzger-Filho O, Winer E, Krop I . Pertuzumab: optimizing HER2 blockade. Clin Cancer Res. 2013; 19(20):5552-6. DOI: 10.1158/1078-0432.CCR-13-0518. View

10.

Gagliato D, Fontes Jardim D, Marchesi M, Hortobagyi G . Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016; 7(39):64431-64446. PMC: 5325455. DOI: 10.18632/oncotarget.7043. View

11.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

12.

Xu Z, Zhang Y, Li N, Liu P, Gao L, Gao X . Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017; 7(3):e013053. PMC: 5353336. DOI: 10.1136/bmjopen-2016-013053. View

13.

Lambert J, Chari R . Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014; 57(16):6949-64. DOI: 10.1021/jm500766w. View

14.

Jhanwar-Uniyal M, Wainwright J, Mohan A, Tobias M, Murali R, Gandhi C . Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul. 2019; 72:51-62. DOI: 10.1016/j.jbior.2019.03.003. View

15.

Zhang X, Chen J, Weng Z, Li Q, Zhao L, Yu N . A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol Immunol. 2020; 119:48-58. DOI: 10.1016/j.molimm.2020.01.009. View

16.

Connell C, Doherty G . Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017; 2(5):e000279. PMC: 5708307. DOI: 10.1136/esmoopen-2017-000279. View

17.

Ferreira D, Soares M, Correia J, Adega F, Ferreira F, Chaves R . Assessment of and gene status and expression profile in feline mammary tumors: findings and guidelines. Aging (Albany NY). 2019; 11(13):4688-4705. PMC: 6660035. DOI: 10.18632/aging.102079. View

18.

Canonici A, Ivers L, Conlon N, Pedersen K, Gaynor N, Browne B . HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Invest New Drugs. 2018; 37(3):441-451. DOI: 10.1007/s10637-018-0649-y. View

19.

Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M . HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013; 141(1):43-53. PMC: 3758835. DOI: 10.1007/s10549-013-2665-0. View

20.

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View